The Quantellect read.As of Nov 19, 2026, 3 active firms cover Telix Pharmaceuticals Limited: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $20.00 to $22.00, so the covering firms are broadly aligned. The average target of $21.33 sits 138% above the current $8.96. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.09 next quarter toward $-0.04 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.33
+138.1% upside
Average target across 3 active firms as of Nov 19, 2026 vs $8.96 current
Highest Target$22.00
Average Target$21.33
Lowest Target$20.00
Detailed analyst forecasts for TLX
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate TLX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TLX EPS & revenue forecast
EPS · NEXT QUARTER
$0.09
Range $0.09 – $0.09 · 1 analysts
Next period, 1 analysts expect Telix Pharmaceuticals Limited to earn $0.09 a share (range $0.09 – $0.09), versus — a year earlier. Full-year consensus is $0.16, growing to $-0.04 the year after.
REVENUE · NEXT QUARTER
$318.8M
Range $267.8M – $354.2M · 1 analysts · +3% YoY
Revenue is expected to reach $318.8M (range $267.8M – $354.2M), +2.9% year-over-year. Full-year consensus is $1.4B, rising to $1.6B next year.
Top analysts covering Telix Pharmaceuticals Limited
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TLX.
#1
David Nierengarten
Wedbush · Rank #24
Buy
$22.00+145.5% to target
Overall win rate
48%
+ Follow
#2
RB
Robert Burns
HC Wainwright & Co. · Rank #215
Buy
$20.00+123.2% to target
Overall win rate
42%
+ Follow
#3
LS
Laura Sutcliffe
Citigroup
Buy
$22.00+145.5% to target
Coverage
—
+ Follow
#4
DD
David Dai
UBS
Buy
$20.00+123.2% to target
Coverage
—
+ Follow
#5
LS
Laura Sutcliffe
UBS
Buy
$22.00+145.5% to target
Coverage
—
+ Follow
TLX stock forecast FAQ
What is TLX's average 12-month price target?+
The 3 active firms with a live target average $21.33 for Telix Pharmaceuticals Limited over the next 12 months, ranging from a $22.00 high to a $20.00 low, as of Nov 19, 2026.
Is TLX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TLX?+
The Street-high target is $22.00 (Wedbush), and the Street-low is $20.00 (HC Wainwright & Co.). The average of all 3 active-firm targets is $21.33.
How many active Wall Street firms cover TLX?+
3 active firms have a recognized rating on Telix Pharmaceuticals Limited as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TLX?+
Among analysts who currently cover TLX, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #24). Their current call is Buy with a $22.00 target.
What is Telix Pharmaceuticals Limited's projected EPS for next quarter?+
The consensus estimate is $0.09 per share (range $0.09 – $0.09) across 1 analysts. Full-year EPS is projected at $0.16, rising to $-0.04 the following year.
How much revenue is Telix Pharmaceuticals Limited expected to report next quarter?+
Consensus revenue is $318.8M (range $267.8M – $354.2M). Full-year revenue is projected at $1.4B, growing to $1.6B next year.
Have analysts been upgrading or downgrading TLX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate TLX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TLX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.